Graft vs Host Disease (GVHD) Treatment Market will grow at a CAGR of 7.15% during 2017-2021: Radiant Insights

0
45

Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient’s adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor’s organ/cell are used for transplantation compared with autologous transplant, a transplant where individual’s cells have been used for transplant.

Covered in this report

The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

To access full, click here: https://www.radiantinsights.com/research/global-graft-vs-host-disease-gvhd-treatment-market-2017-2021

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche

Other prominent vendors

  • Abbott
  • AbbVie
  • Allergan
  • Anterogen
  • Astellas Pharma
  • Athersys
  • Baxter
  • Caladrius
  • Cellular Biomedicine Group
  • Cipla
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Incyte Corporation
  • IPCA Laboratories
  • Kadmon Holdings
  • Lupin
  • Osiris Therapeutics
  • RedHill
  • Sanofi
  • Shire
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • ViaCyte

Request free sample copy of this report @ https://www.radiantinsights.com/research/global-graft-vs-host-disease-gvhd-treatment-market-2017-2021/request-sample

Market driver

  • Increased prevalence of cancer
  • For a full, detailed list, view our report

Market challenge

  • Off-label use of drugs
  • For a full, detailed list, view our report

Market trend

  • Inorganic growth strategies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Leave a Reply